Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Compugen has announced the discovery and experimental verification of CGEN-144, a novel variant of Troponin I biomarker, and the signing of a research and license option agreement with Biosite.
Subscribe to our email newsletter
Compugen also received a patent for this biomarker from the US Patent and Trademark Office. Under the recently signed agreement with Biosite, Compugen will provide Biosite with all existing proprietary data related to the molecule and Biosite will develop and select antibodies that bind to CGEN-144 to determine assay sensitivity and specificity in various disease states and as an addition to the current commercial Troponin I test.
The agreement also provides Biosite with an option to obtain worldwide royalty bearing commercialization rights for possible immunoassay diagnostic products based on this biomarker.
The novel Troponin I variant was one of a group of putative cancer and cardiovascular biomarkers previously predicted by Compugen’s immunoassay biomarker computational discovery platform. The molecule has subsequently been experimentally verified to be differentially expressed – as serum protein – in myocardial infarction patients compared to healthy individuals.
Alex Kotzer, president and CEO of Compugen, said: “Biosite is a premier partner to further evaluate, and if successful, commercialize this Troponin diagnostic marker given their leading position in cardiovascular diagnostics.”